X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA IPCA LABS AJANTA PHARMA/
IPCA LABS
 
P/E (TTM) x 20.0 28.2 70.8% View Chart
P/BV x 4.6 3.3 138.5% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 AJANTA PHARMA   IPCA LABS
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
IPCA LABS
Mar-18
AJANTA PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,818695 261.4%   
Low Rs1,106400 276.5%   
Sales per share (Unadj.) Rs239.5260.2 92.0%  
Earnings per share (Unadj.) Rs52.819.0 278.3%  
Cash flow per share (Unadj.) Rs59.533.1 180.0%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs230.0213.0 107.9%  
Shares outstanding (eoy) m88.77126.20 70.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.12.1 290.0%   
Avg P/E ratio x27.728.9 95.9%  
P/CF ratio (eoy) x24.616.6 148.3%  
Price / Book Value ratio x6.42.6 247.3%  
Dividend payout %05.3 0.0%   
Avg Mkt Cap Rs m129,78269,120 187.8%   
No. of employees `0006.813.3 51.3%   
Total wages/salary Rs m3,7657,359 51.2%   
Avg. sales/employee Rs Th3,128.42,477.4 126.3%   
Avg. wages/employee Rs Th554.0555.2 99.8%   
Avg. net profit/employee Rs Th689.7180.6 381.8%   
INCOME DATA
Net Sales Rs m21,25832,836 64.7%  
Other income Rs m242418 57.8%   
Total revenues Rs m21,49933,254 64.7%   
Gross profit Rs m6,5844,505 146.2%  
Depreciation Rs m5961,777 33.5%   
Interest Rs m4240 1.7%   
Profit before tax Rs m6,2262,905 214.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,539511 301.1%   
Profit after tax Rs m4,6862,394 195.7%  
Gross profit margin %31.013.7 225.8%  
Effective tax rate %24.717.6 140.5%   
Net profit margin %22.07.3 302.4%  
BALANCE SHEET DATA
Current assets Rs m12,23619,455 62.9%   
Current liabilities Rs m3,46110,076 34.3%   
Net working cap to sales %41.328.6 144.5%  
Current ratio x3.51.9 183.1%  
Inventory Days Days6098 61.5%  
Debtors Days Days8467 126.2%  
Net fixed assets Rs m11,14020,260 55.0%   
Share capital Rs m177252 70.1%   
"Free" reserves Rs m20,23726,633 76.0%   
Net worth Rs m20,41426,886 75.9%   
Long term debt Rs m102,340 0.4%   
Total assets Rs m24,48641,173 59.5%  
Interest coverage x1,519.413.1 11,602.7%   
Debt to equity ratio x00.1 0.6%  
Sales to assets ratio x0.90.8 108.9%   
Return on assets %19.26.4 299.4%  
Return on equity %23.08.9 257.8%  
Return on capital %30.510.8 283.4%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m11,66715,642 74.6%   
Fx outflow Rs m1,6164,884 33.1%   
Net fx Rs m10,05210,759 93.4%   
CASH FLOW
From Operations Rs m2,8543,411 83.7%  
From Investments Rs m-2,604-1,354 192.3%  
From Financial Activity Rs m-2-1,304 0.2%  
Net Cashflow Rs m248753 32.9%  

Share Holding

Indian Promoters % 73.8 45.9 160.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 11.4 13.6%  
FIIs % 7.6 25.3 30.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 17.4 97.7%  
Shareholders   20,968 36,892 56.8%  
Pledged promoter(s) holding % 4.4 2.1 205.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   VENUS REMEDIES  SHASUN PHARMA  SANOFI INDIA  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Red, Global Markets Cautious, and Top Stocks in Action(Pre-Open)

On Monday, share markets in India opened on a positive note and ended the day in red after a volatile day of trading.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Nov 12, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - ORCHID PHARMA LTD COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS